Postoperative Morbidity and Mortality After Gastric Cancer Surgery
Launched by P. HERZEN MOSCOW ONCOLOGY RESEARCH INSTITUTE · Feb 18, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the outcomes of surgery for gastric cancer, specifically looking at the complications and risks that patients may face after their surgery. Gastric cancer is a serious condition, and surgery is currently the best option for a cure. However, the results of surgery can vary widely depending on where the procedure is performed. The researchers want to study how many patients experience complications and deaths within 90 days after surgery across different hospitals in Russia. This information will help improve future treatment guidelines.
To participate in this trial, patients should be adults aged 18 or older who have been diagnosed with primary gastric cancer and are scheduled for elective surgery with the aim of curing their cancer. Unfortunately, patients with certain other types of cancer or those needing emergency surgery won't be eligible. If you join the trial, you can expect to be closely monitored after your surgery to track any complications and to provide valuable information that could help improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All consecutive patients with primary gastric malignancy (including Siewert III) undergoing elective surgery with curative intent (either total or partial gastrectomy) via open, laparoscopic or robotic approach between 18th March 2024 and 18th September 2024.
- Exclusion Criteria:
- • Patients with clinical evidence of metastatic disease, including positive peritoneal cytology on previous staging laparoscopy,
- • Patients with known synchronous cancer;
- • Patients with Gastrointestinal stromal tumors (GIST)
- • Presence of gastroesophageal junction (Siewert I and II) malignancy;
- • Patients submitted to Emergency surgery or surgery without curative intent;
- • Patients undergoing additional surgery (except cholecystectomy) along with surgery for gastric cancer.
About P. Herzen Moscow Oncology Research Institute
The P. Herzen Moscow Oncology Research Institute is a leading clinical research organization dedicated to advancing cancer treatment and care. With a rich history in oncology research, the institute focuses on innovative therapies and comprehensive clinical trials aimed at improving patient outcomes. By integrating cutting-edge scientific methods with clinical expertise, the institute fosters collaboration among researchers, healthcare professionals, and patients to drive breakthroughs in cancer treatment. Its commitment to excellence and patient-centered care positions it as a prominent sponsor in the field of oncology research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Rostov On Don, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Nizhny Novgorod, , Russian Federation
Saint Petersburg, , Russian Federation
Patients applied
Trial Officials
Andrey Ryabov, MD, PhD
Study Director
P.Herzen Moscow Oncological Research Institute
Vladimir Khomyakov, MD, PhD
Principal Investigator
P.Herzen Moscow Oncological Research Institute
Nuriddin Abdulkhakimov, MD, PhD
Principal Investigator
P.Herzen Moscow Oncological Research Institute
Pavel Smirnov
Principal Investigator
P.Herzen Moscow Oncological Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported